BBP-398

N/A

Report date: 2024/11/27 20:00:40
NME

Base Information

Drug NameBBP-398
Drug Alias NameIACS-15509BBP-398IACS-13909BMS-986466
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSrc homology phosphotyrosyl phosphatase 2 inhibitors
TargetsSrc homology phosphotyrosyl phosphatase 2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsItaly +[11] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBridgebio Pharma IncThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesBridgebio Pharma IncShanghai LianBio Development Co Ltd
Inactive CompaniesBristol Myers Squibb SrlcompanyCorealis Pharma IncAmgen Inc +[4] 
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A